News and Media
News and Media
Half-year liquidity contract statement for Valerio Therapeutics
January 25, 2024
Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities (English)
New identity unveiled, with the aim at developing innovative therapies [...]
September 28, 2023
Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023 (English)
All the resolutions approved by the Board of Directors were [...]
June 6, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures (English)
May 16, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures
May 16, 2023
Publication of the 2022 Annual Financial Report
April 28, 2023
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
April 24, 2023
Onxeo will publish its full-year results on April 24, 2023
April 21, 2023
Onxeo will publish its full-year results on April 14, 2023
March 14, 2023
Onxeo: report on the Extraordinary General Meeting of February 6, 2023
February 6, 2023
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
November 30, 2022
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
November 30, 2022
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
September 13, 2022
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
September 1, 2022
Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen
August 30, 2022
Press Release Signup
Subscribe to receive our Press Releases when they come out.
